Free Trial
NASDAQ:CYCC

Cyclacel Pharmaceuticals (CYCC) Stock Price, News & Analysis

Cyclacel Pharmaceuticals logo
$8.97 +1.56 (+21.05%)
Closing price 08/7/2025 04:00 PM Eastern
Extended Trading
$9.07 +0.10 (+1.17%)
As of 08/7/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Cyclacel Pharmaceuticals Stock (NASDAQ:CYCC)

Key Stats

Today's Range
$7.45
$9.77
50-Day Range
$0.23
$25.05
52-Week Range
$3.08
$597.60
Volume
458,368 shs
Average Volume
5.20 million shs
Market Capitalization
$14.17 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Hold

Company Overview

Cyclacel Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
11th Percentile Overall Score

CYCC MarketRank™: 

Cyclacel Pharmaceuticals scored higher than 11% of companies evaluated by MarketBeat, and ranked 896th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Cyclacel Pharmaceuticals is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Cyclacel Pharmaceuticals is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Cyclacel Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    7.79% of the float of Cyclacel Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Cyclacel Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cyclacel Pharmaceuticals has recently increased by 9,369.23%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Cyclacel Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Cyclacel Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    7.79% of the float of Cyclacel Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Cyclacel Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cyclacel Pharmaceuticals has recently increased by 9,369.23%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Cyclacel Pharmaceuticals has a news sentiment score of -0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Cyclacel Pharmaceuticals this week, compared to 1 article on an average week.
  • Search Interest

    17 people have searched for CYCC on MarketBeat in the last 30 days. This is an increase of 183% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Cyclacel Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Cyclacel Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $83,430.00 in company stock.

  • Percentage Held by Insiders

    51.20% of the stock of Cyclacel Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 23.58% of the stock of Cyclacel Pharmaceuticals is held by institutions.

  • Read more about Cyclacel Pharmaceuticals' insider trading history.
Receive CYCC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cyclacel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CYCC Stock News Headlines

The End of Elon Musk…?
The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.
Cyclacel Pharmaceuticals, Inc. (CYCCP) - Yahoo Finance
See More Headlines

CYCC Stock Analysis - Frequently Asked Questions

Cyclacel Pharmaceuticals' stock was trading at $90.24 at the start of the year. Since then, CYCC shares have decreased by 90.1% and is now trading at $8.97.

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) issued its quarterly earnings data on Wednesday, April, 2nd. The biotechnology company reported ($79.20) EPS for the quarter, missing analysts' consensus estimates of ($69.60) by $9.60. The biotechnology company earned $0.01 million during the quarter, compared to analyst estimates of $0.01 million.

Cyclacel Pharmaceuticals's stock reverse split on the morning of Monday, July 7th 2025.The 1-15 reverse split was announced on Wednesday, July 2nd 2025. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 3rd 2025. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Shares of CYCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cyclacel Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), GE Aerospace (GE), Broadcom (AVGO), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY) and Arista Networks (ANET).

Company Calendar

Last Earnings
4/02/2025
Today
8/07/2025
Next Earnings (Estimated)
8/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CYCC
CIK
1130166
Employees
14
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($839.58)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$11.21 million
Net Margins
N/A
Pretax Margin
-55,535.71%
Return on Equity
-3,648.09%
Return on Assets
-155.99%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.60
Quick Ratio
5.60

Sales & Book Value

Annual Sales
$40 thousand
Price / Sales
354.32
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($58.87) per share
Price / Book
-0.15

Miscellaneous

Outstanding Shares
1,580,000
Free Float
773,000
Market Cap
$14.17 million
Optionable
Optionable
Beta
0.08

Social Links

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:CYCC) was last updated on 8/8/2025 by MarketBeat.com Staff
From Our Partners